On Tuesday, Vir Biotechnology (NASDAQ:VIR) maintained its Overweight rating and a $27.00 price target from Barclays (LON:BARC). The firm's positive stance comes ahead of the biotechnology company's Phase 2 SOLSTICE trial data update, which is scheduled to be presented at the European Association for the Study of the Liver (EASL) on June 5.
Barclays' assessment highlighted the significant unmet medical need for hepatitis delta (HDV) treatments. The current therapies, such as pegylated interferon-alpha (peg-IFN-α) in the United States and bulevirtide in the European Union, were deemed suboptimal.
The firm's analysis pointed out that Vir Biotechnology's combination of elebsiran (siRNA) and tobevibart (mAb) has shown promising early results, with a 100% virological response rate (6 out of 6 patients) achieving a 2 log reduction or undetectable HDV-RNA levels.
Feedback from key opinion leaders (KOLs) indicates that the current virological response rate and the alanine aminotransferase (ALT) normalization rate nearing 60% at 24 weeks would be considered clinically meaningful. A sustained virologic response rate of approximately 50% would be seen as practice changing, according to the KOLs consulted.
Barclays also noted that the current diagnosed HDV population in the United States, estimated between 10,000 to 20,000 individuals out of a prevalence of around 100,000, is likely underestimated due to limited screening.
This suggests a potential market for effective treatments such as the ones being developed by Vir Biotechnology. The upcoming data presentation at EASL is anticipated to provide further insights into the efficacy and potential of Vir's therapeutic candidates.
InvestingPro Insights
Following Barclays' optimistic outlook on Vir Biotechnology, InvestingPro data reveals a mixed financial landscape for the company. With a market capitalization of $1.32 billion and a concerning negative P/E ratio of -2.61 for the last twelve months as of Q1 2024, investors are keenly observing the company's financial health. The company's significant cash reserves, as highlighted by an InvestingPro Tip, provide some stability, as they hold more cash than debt on their balance sheet. However, the company's rapid cash burn and analysts' expectations of a sales decline this year are points of caution. On a positive note, the stock has experienced a strong return over the last month, with a 21.89% price total return, indicating some investor confidence leading up to the EASL presentation.
InvestingPro Tips further reveal that while analysts have revised their earnings upwards for the upcoming period, they do not anticipate the company will be profitable this year. Additionally, despite Vir's liquid assets exceeding short-term obligations, the company has not been profitable over the last twelve months. For investors looking to delve deeper into Vir Biotechnology's financials and future prospects, InvestingPro offers a wealth of additional tips. There are currently 9 more tips available, which can be accessed with an exclusive offer: use coupon code PRONEWS24 for an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.